2153 related articles for article (PubMed ID: 20029421)
1. Integrins in cancer: biological implications and therapeutic opportunities.
Desgrosellier JS; Cheresh DA
Nat Rev Cancer; 2010 Jan; 10(1):9-22. PubMed ID: 20029421
[TBL] [Abstract][Full Text] [Related]
2. Small molecule integrin antagonists in cancer therapy.
Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
[TBL] [Abstract][Full Text] [Related]
3. Targeting integrins in malignant glioma.
Tabatabai G; Weller M; Nabors B; Picard M; Reardon D; Mikkelsen T; Ruegg C; Stupp R
Target Oncol; 2010 Sep; 5(3):175-81. PubMed ID: 20820929
[TBL] [Abstract][Full Text] [Related]
4. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Scaringi C; Minniti G; Caporello P; Enrici RM
Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
[TBL] [Abstract][Full Text] [Related]
5. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Reardon DA; Nabors LB; Stupp R; Mikkelsen T
Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418
[TBL] [Abstract][Full Text] [Related]
6. The role of integrins in glioma biology and anti-glioma therapies.
Tabatabai G; Tonn JC; Stupp R; Weller M
Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
[TBL] [Abstract][Full Text] [Related]
9. Cilengitide treatment for malignant glioma: current status and future direction.
Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
[TBL] [Abstract][Full Text] [Related]
10. Integrins: molecular targets in cancer therapy.
Tucker GC
Curr Oncol Rep; 2006 Mar; 8(2):96-103. PubMed ID: 16507218
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Reardon DA; Neyns B; Weller M; Tonn JC; Nabors LB; Stupp R
Future Oncol; 2011 Mar; 7(3):339-54. PubMed ID: 21417900
[TBL] [Abstract][Full Text] [Related]
12. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
13. Every step of the way: integrins in cancer progression and metastasis.
Hamidi H; Ivaska J
Nat Rev Cancer; 2018 Sep; 18(9):533-548. PubMed ID: 30002479
[TBL] [Abstract][Full Text] [Related]
14. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
Sheldrake HM; Patterson LH
J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
[TBL] [Abstract][Full Text] [Related]
15. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
[TBL] [Abstract][Full Text] [Related]
16. Integrins regulate stemness in solid tumor: an emerging therapeutic target.
Xiong J; Yan L; Zou C; Wang K; Chen M; Xu B; Zhou Z; Zhang D
J Hematol Oncol; 2021 Oct; 14(1):177. PubMed ID: 34715893
[TBL] [Abstract][Full Text] [Related]
17. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
18. Integrins Within the Tumor Microenvironment: Biological Functions, Importance for Molecular Targeting, and Cancer Therapeutics Innovation.
Dzobo K
OMICS; 2021 Jul; 25(7):417-430. PubMed ID: 34191612
[TBL] [Abstract][Full Text] [Related]
19. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
[TBL] [Abstract][Full Text] [Related]
20. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
